Advertisement

Topics

ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017

13:39 EDT 20 Mar 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS p...

Other Sources for this Article

ERYTECH
Gil Beyen
Chairman and CEO
or
Eric Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
or
The Ruth Group
Lee Roth, +1 646 536 7012
Investor relations
lroth@theruthgroup.com
or
Kirsten Thomas, +1 508 280 6592
Media relations
kthomas@theruthgroup.com
or
NewCap
Julien Perez
Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

NEXT ARTICLE

More From BioPortfolio on "ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017"

Quick Search
Advertisement
 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...